|Bid||18.06 x 200|
|Ask||18.07 x 600|
|Day's Range||16.70 - 18.24|
|52 Week Range||16.70 - 18.24|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Moody's Investors Service ("Moody's") affirmed certain ratings of Bausch Health Companies Inc. ("Bausch") and its subsidiaries, and revised the rating outlook to positive from stable. In addition, Moody's upgraded Bausch's Speculative Grade Liquidity Rating to SGL-1 from SGL-2.
Valeant Pharmaceuticals International changed its name to Bausch Health (BHC), but Piper Jaffray's David Amsellem thinks the stock is a sell no matter what you call it. Amsellem reiterated an Underweight rating on Bausch on Monday, writing that the while the name change "refreshingly consigns the Valeant name to the dustbin of pharma history," and while that may help the company put some missteps behind it, he still has "myriad concerns regarding the commercial portfolio and pipeline." He writes that it's still too soon to say when and where Bausch's earnings before interest, taxes, depreciation and amortization will trough. The recent tentative approval of a generic form of the non-steroid anti-inflammatory drug Apriso only serves to further highlight the company's "significant exposure to loss of exclusivities." Moreover, Amsellem writes that data points about new drug launches, specifically inflammatory treatment Siliq and eye drug Vyzulta "are suggestive of underwhelming traction." Given this, along with the company's exposure to mature assets with "questionable durability and leverage ratios that are still very much an eyesore" he thinks Bausch's valuation of 10 times enterprise value to Ebitda is still too high.
A strong first-quarter sent the pharmaceutical company's shares northward, but this positive momentum is starting to fade after a key regulatory setback.
Valeant Pharmaceuticals (VRX), now known as Bausch Health Companies (BHC), generated revenues of $2 billion in the first quarter compared to $2.1 billion in the first quarter of 2017, reflecting a 5% YoY (year-over-year) decline.
In July, the FDA accepted Bausch + Lomb’s NDA (New Drug Application) for sub-micron loteprednol etabonate for the treatment of patients who have undergone ocular surgery and are showing symptoms of post-operative inflammation and pain.
Investors in Valeant Pharmaceuticals (VRX) need to pay close attention to the stock based on moves in the options market lately.
Celgene Corporation (NASDAQ:CELG) stock looks attractive here, for a number of reasons. Celgene stock has sold off, losing about 43% of its value. Celgene touched a four-year low in May before a recent rebound. The decline leaves Celgene looking awfully cheap, at a little over 8.3x 2019 consensus EPS estimates.
PDUFA Date Set for February 25, 2019 LAVAL, Quebec , July 9, 2018 /PRNewswire/ -- – Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Valeant Pharmaceuticals International, ...
On July 3, the Financial Times reported that Pfizer Inc. (NYSE:PFE) is increasing the prices of 100 of its drugs by around 10 percent. Value investors looking to buy in should stick with drug stocks trading at favorable valuations and whose business faces multiple positive catalysts ahead. Here are 5 biotech stocks to get you started for July.
A controversy over massive price increases, along with other scandals, wrecked Valeant Pharmaceutical International Inc.’s reputation as well as its stock price in recent years. Valeant (VRX) is using two techniques to raise prices on one of its best-selling drugs: it has increased the size of the package of its diarrhea medication, called Xifaxan, by 43%, from 42 pills to 60, and it is charging about 6% more per milligram, according to an analyst note by Mizuho’s Irina Koffler. The larger packaging has helped boost sales volumes, Koffler said.
Shares of Valeant Pharmaceuticals International (VRX) sold off earlier this month after the company received a Complete Response Letter from the Food and Drug Administration concerning its plaque psoriasis Duobrii. However, Mizuho's Irina Koffler argues that the selloff is overdone, as she believes that Xifaxan, the traveler's diarrhea and irritable-bowel-syndrome treatment, is Valeant's key growth driver, rather than its dermatology portfolio. She reiterated a Buy rating on Valeant Friday and raised her price target by $4 to $31. The SPDR S&P Pharmaceuticals ETF (XPH) is up 0.5% to $43.18 and the Health Care Select Sector SPDR ETF (XLV) is up 0.8% to $83.92.
Valeant Pharmaceuticals (VRX) stock has been falling in June. Valeant’s division Ortho Dermatologics received a CRL (complete response letter) from the FDA on June 18 for its new drug application for Duobril, which treats plaque psoriasis. Valeant’s Siliq, which treats moderate to severe psoriasis, received FDA approval earlier.
Stock Research Monitor: QTNT, ADMP, and PETS LONDON, UK / ACCESSWIRE / June 28, 2018 / If you want a free Stock Review on VRX sign up now at www.wallstequities.com/registration . On Wednesday, June 27, ...
By now, we've all heard of the horrors of the U.S. opioid crisis: Well over 100 people a day die by opioid overdose, and a quarter of all patients who are prescribed opioids for chronic pain–11.5 million people–end up misusing the medications. Valeant is off 0.5% to $23.19 this morning.
Salix Sales Force to Begin Promoting LUCEMYRA to Primary Care and Pain Management Physicians LUCEMYRA is the First and Only Non-Opioid Medication Approved for Mitigation of Opioid Withdrawal Symptoms LOUISVILLE, ...
NEW YORK, NY / ACCESSWIRE / June 23, 2018 / Pomerantz LLP is investigating claims on behalf of investors of Valeant Pharmaceuticals International, Inc. ("Valeant" or the "Company") (VRX). Such investors are advised to contact Robert S. Willoughby at firstname.lastname@example.org or 888-476-6529, ext. 9980. The investigation concerns whether Valeant and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
Jim Cramer shares his take on callers' favorite stocks at lightning speed, including a much debated social media play.
Cindy Eckert is the anti-Martin Shkreli — after the billion-dollar Valeant debacle, the founder of Sprout Pharmaceuticals is back as CEO and she's slashed the price of the little pink libido pill for women. Here's what she learned from the experience and where she goes from here.
NEW YORK , June 19, 2018 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Valeant Pharmaceuticals International, Inc. ("Valeant" or the "Company") (NYSE: VRX). ...
NEW YORK , June 19, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Valeant Pharmaceuticals International, Inc. ...
Bausch Health Companies, formerly known as Valeant Pharmaceutical International Inc., began trading under its new name today. CEO Joseph Papa discusses the new name and what other changes were made in an exclusive interview.
Eckert stopped by Fortune to talk about her "real launch" of Sprout's Addyi after getting it back from Valeant Pharmaceuticals.